Stocks in news: HFCL, BHEL, Glenmark Pharma, ABFRL, Wipro

Equity markets remained volatile on Friday, shedding nearly half a percent amid mixed cues. In today's trade, shares of HFCL, BHEL, Glenmark Pharma, ABFRL, Wipro among others will be in focus due to various news developments.

HFCL
Domestic telecom gear maker HFCL is betting big on growth from overseas sales and uptake of defence supplies as the company looks to become a Rs 10,000-crore revenue enterprise, a top company official said.

Piramal Enterprises
Piramal Enterprises Board approved the issuance of secured, rated, listed, and redeemable non-convertible debentures (NCDs) worth up to Rs 450 crore on a private placement basis.


Glenmark Pharma
Glenmark Pharma's consolidated profit after tax stood at Rs 348 crore for the third quarter ended December 2024, aided by strong performance across regions. The company reported a loss in the comparable year-ago quarter.

Bank of India
State-owned Bank of India announced that it had raised Rs 2,690 crore through 10-year infrastructure bonds at a coupon rate of 7.50% per annum.

Zen Technologies
Defence training solutions provider Zen Technologies announced strategic investments in Vector Technics and Bhairav Robotics.

ABFRL
ABFRL reported narrowing of its losses in the third quarter to Rs 51 crore as revenue from operations grew 3% year-on-year to Rs 4,305 crore.

BHEL
BHEL received a letter of intent (LoI) for EPC Package for Singareni Thermal Power Project, Stage II (1x800 MW) at Mancherial district, Telangana worth Rs 6,700 crore.

Wipro
Wipro appointed Amit Kumar as the managing partner and global head of Wipro Consulting effective immediately.

Alembic Pharma
Alembic Pharma received an establishment inspection report (EIR) from US FDA for Vadodara’s Jarod-based Solid Oral Formulation Facility (F-4) with Voluntary Action Indicated (VAI) classification.

Zydus Lifesciences
US FDA completed inspection of the company's Maharashtra’s Ambernath-based API manufacturing site with NIL observations.